404844-11-7

Basic information

• Product Name: 4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
• Synonyms: N-[5[[4-(Chloromethyl)benzoyl]amino]-2-methylphenyl]4-(3-pyridyl)-2-pyrimidine;4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide;N-[5-[[4-(Chloromethyl)benzoyl]amino]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidineamine;IMatinib interMediate (N-[4-Methyl-3-(4-pyridin-3-yl-pyriMidin-2-ylaMino)-phenyl]-4-ChloroMethyl BenzaMide);4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide N-[5-[[4-(Chloromethyl)benzoyl]amino]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidineamine;Imatinib genotoxic impurity D9
• CAS NO: 404844-11-7
• Molecular Formula: C₂₄H₂₀ClN₅O
• Molecular Weight: 429.9
• EINECS: 1312995-182-4
• Product Categories: Nucleotides and Nucleosides;Bases & Related Reagents;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals
• Mol File: 404844-11-7.mol
• Article Data: 28

Chemical Properties

• Melting Point: 300°C (dec)
• Appearance: Off-white solid
• Density: 1.329
• Refractive Index: 1.691
• Storage Temp.: -20°C Freezer
• PKA: 12.99±0.70(Predicted)
• CAS DataBase Reference: 4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide(404844-11-7)
• EPA Substance Registry System: 4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide(404844-11-7)

Safety Data

• Hazardous Substances Data: 404844-11-7(Hazardous Substances Data)

Usage

Chemical Properties

Off-White Solid

Uses

Gleevec Impurity

InChI:InChI=1/C24H20ClN5O/c1-16-4-9-20(28-23(31)18-7-5-17(14-25)6-8-18)13-22(16)30-24-27-12-10-21(29-24)19-3-2-11-26-15-19/h2-13,15H,14H2,1H3,(H,28,31)(H,27,29,30)

Upstream product

• 1642-81-5 p-(chloromethyl)benzoic acid 
• 55314-16-4 (E)-3-(dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one 
• 3006-96-0 3-hydroxymethyl-benzoic acid 
• 7745-93-9 2-bromo-4-nitrotoluene 
• 99-99-0 1-methyl-4-nitrobenzene 
• 1692-25-7 3-pyridylboronic acid 
• 66521-66-2 4-pyridin-3-ylpyrimidin-2-ylamine 
• 152460-10-1 6-methyl-1-N-(4-(pyridin-3-yl)pyrimidin-2-yl)benzene-1,3-diamine 
• 876-08-4 p-(chloromethyl)benzoyl chloride 
• 99-55-8 2-methyl-5-nitroaniline 
• 152460-08-7 1-(2-methyl-5-nitrophenyl)guanidine nitrate 
• 152460-09-8 N-(5-nitro-2-methylphenyl)-4-(3-pyridinyl)-2-pyrimidineamine 
• 55314-16-4 3-(N,N-dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one 
• 350-03-8 methyl-3-pyridylketone 

Downstream Products

• 220127-57-1 imatinib mesylate 
• 1321600-78-5 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[[4-(3-pyridinyl)-2-pyrimidinyl]-N-acetyl]amino]phenyl]benzamide 
• 404843-96-5 4-((dimethylamino)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide 
• 1089724-90-2 4-(acrylamidomethyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide 

Relevant articles and documents

Synthesis of Novel Derivatives of 1-Metoxy-3-methylcarbazole – Murrayafoline A Alkaloid

Abstract: The paper presents the results of a study on the synthesis of new derivatives of the murrayafoline alkaloid, potential inhibitors of tumor processes, which combine in their structure 2 chromatophores: 2-aminopyrimidine and murrayafoline. Pyrimid

Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects

The BCR-ABL fusion oncoprotein causes chronic myeloid leukemia or acute lymphoblastic leukemia in Ph+ patients because the ABL kinase is constitutively activated. However, current clinical treatment with ABL inhibitors is seriously limited by drug resistance and adverse effects. Although the emerging proteolysis-Targeting chimeras (PROTACs) have been introduced to degrade BCR-ABL, most of them showed limited activity and could not overcome the common drug-resistant mutants, especially for T315I mutant. Herein, we systematically designed a set of unique PROTACs by globally targeting all the three binding sites of BCR-ABL, including dasatinib-, ponatinib-, and asciminib-based PROTACs. Our ponatinib-based PROTACs showed practical activity as dasatinib-based PROTACs, while no reported ponatinib-based PROTACs could degrade BCR-ABL before. As a proof of concept, some additional dasatinib-based PROTACs were then designed to degrade T315I mutant too. We provided a global PROTAC toolbox for degrading both wild-Type and T315I-mutated BCR-ABL from each binding site. More importantly, these PROTACs showed better selectivity and less adverse effects than the inhibitors, indicating that PROTACs had great potential for overcoming clinical drug resistance and safety issues.

Novel PDGFR kinases inhibitor and purpose thereof

The invention provides a novel PDGFR kinases inhibitor, which comprises a compound shown in a formula (I) or its pharmaceutical acceptable salt, a solvate, ester, acid, a metabolite, or a prodrug. Theinvention also provides a purpose of the compound shown